Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan
Shots:
- The Taiwan Ministry of Health and Welfare granted conditional approval to initiate P-II trial of UB-612 in 3-850 subjects including adolescents- adults- and seniors across 11 medical centers and hospitals in Taiwan
- Additionally- Covaxx collaborated with UNMC to conduct clinical trials in the US- and with Dasa S.A. to conduct P-II/III study and distribute vaccines within Brazil. Covaxx also collaborated with Aurobindo to distribute the vaccine in India and UNICEF
- COVAXX is in production for the first 100M doses and subsequently over 500M doses in 2021
Ref: PRNewswire | Image: COVAXX
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com